Abstract
A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have